Nrf2 in cancers: A double-edged sword.

Wu S, Lu H, Bai Y. · 2019

Read Nrf2 in cancers: A double-edged sword. by Wu S, Lu H, Bai Y. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6536957.txt.

Introduction

Wu, Lu and Bai review the two faces of Nrf2, a master switch for cellular defense, writing in Cancer Medicine. Held in check by its partner Keap1, Nrf2 wakes under oxidative stress and turns on a battery of protective genes. That shield prevents cancer, fights inflammation and keeps redox balance — in healthy cells.

Established tumors hijack the same switch. Many cancers lock Nrf2 permanently on, and the shield becomes armor: metabolism rewires, cell death is repressed, stem-like cells renew themselves, and chemotherapy and radiation lose their bite. Patients fare worse for it. The review weighs this double edge and surveys Nrf2 inhibitors in development, arguing that disarming the shield could become a real cancer strategy.

Catalog record

CREATORWu S, Lu H, Bai Y.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE81 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6536957

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Nrf2 in cancers: A double‐edged sword By Shijia Wu, Hong Lu, Yongheng Bai Published in: Cancer Medicine DOI: 10.1002/cam4.2101 ABSTRACT Abstract The Nrf2/Keap1 pathway is an important signaling cascade responsible for the resistance of oxidative damage induced by exogenous chemicals. It maintains the redox homeostasis, exerts anti‐inflammation and anticancer activity by regulating its multiple downstream cytoprotective genes, thereby plays a vital role in cell survival. Interestingly, in recent years, accumulating evidence suggests that Nrf2 has a contradictory role in cancers. Aberrant activation of Nrf2 is associated with poor prognosis. The constitutive activation of Nrf2 in various cancers induces pro‐survival genes and promotes cancer cell proliferation by metabolic reprogramming, repression of cancer cell apoptosis, and enhancement of self‐renewal capacity of cancer stem cells. More importantly, Nrf2 is proved to contribute to the chemoresistance and radioresistance of cancer cells as well as inflammation‐induced carcinogenesis. A number of Nrf2 inhibitors discovered for cancer treatment were reviewed in this report. These provide a new strategy that targeting Nrf2 could be a promising therapeutic approach against cancer. This review aims to summarize the dual effects of Nrf2 in cancer, revealing its function both in cancer prevention and inhibition, to further discover novel anticancer treatment. INTRODUCTION Nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) encoded by NFE2L2 gene belongs to a transcription factor subfamily with a Cap “n” Collar (CNC) structure and contains a basic leucine zipper DNA binding domain (b‐Zip) at the C terminus. Nrf2 possesses six highly conserved domains named Nrf2‐ECH homology (Neh) domains. The bZip in Neh1 domain allows Nrf2 to heterodimerize with small musculoaponeurotic fibrosarcoma proteins (sMafs).1 The Neh2 domain allows Nrf2 to bind and regulate its cytoplasmic chaperone molecule Kelch‐like‐ECH‐associated protein 1 (Keap1) in physiological manner.2 The two motifs of Neh2 domain, ETGE and DLG, bind to similar sites on the bottom surface of the Keap1 Kelch motif.3 Neh3 domain is necessary for protein stability and transcriptional activation.4 Neh4 and Neh5 function as two transactivation domains by interacting with CREB‐binding protein (CBP).2 Neh6 domain is rich in serine residues and contains a degron that is involved in the degradation of Nrf2 in oxidatively stressed cells.5 The activity of this degron could be increased by glycogen synthase kinase‐3 (GSK‐3) activity, suggesting that the stimulation of the degron of Neh6 domain could be an effective method to overcome the constitutive upregulation of Nrf2.6 NRF2 ACTIVATION Keap1/Nrf2/ARE signaling pathway The Keap1‐Nrf2 system is of primary importance in maintaining cellular homeostasis in order to respond adaptively to xenobiotic and oxidative stress. Under basal condition, Nrf2 interacts with two molecules of Keap1 through its Neh2 ETGE and DLG motifs to activate Cullin 3 (Cul3)‐based E3 ligase complex‐mediated Nrf2 ubiquitination reaction.7 Once Nrf2 is ubiquitinated, it will be rapidly degraded by 26S proteasome and maintained at a very low level in the cytoplasm.8 On exposure of cells to oxidative stress or chemopreventive compounds, the cysteine residues of Keap1 are modified and the conformation changes, resulting in the detachment of Nrf2 DLG motifs from Keap1, disrupting the ubiquitination and degradation of Nrf2. The binding affinity between Nrf2 and Keap1 is reduced and the ubiquitination system of Nrf2‐Cul3 is disrupted. This allows the de novo‐synthesized Nrf2 to translocate into nucleus, forms a heterodimer with one of sMafs, and binds to antioxidant element (ARE) in the upstream promoter region of multiple genes. On recovery of the redox balance, Nrf2 is dissociated from the ARE sequence. Keap1 enters into the nucleus and escorts Nrf2 out of the nucleus to the cytoplasmic Cul3‐E3 ubiquitin ligase machinery for degradation. Ultimately, a low level of Nrf2 is reattained; the Nrf2/Keap1 signaling pathway is switched off (Figure 1).9, 10 [Figure: Nrf2/Keap1 signaling pathway. Under basal conditions, Nrf2 binds to Keap1 by its two motifs (ETGE and DLG) and activates Cul3‐mediated ubiquitination followed by proteasomal degradation. Under stress conditions, due to the modification of Keap1 cysteine residues, Nrf2 dissociates from Keap1 and translocates into the nucleus. Nrf2 then forms a heterodimer with sMaf protein and binds to ARE to initiate the transcription of various downstream genes] Downstream targets of Nrf2 The Nrf2 downstream targets are classified into three major groups: phase I and phase II drug metabolizing enzymes as well as phase III drug transporters (Table 1). Briefly, phase I enzymes oxidize drugs or xenobiotics; while phase II enzymes conjugate products of phase I reactions, phase III enzymes transport the final metabolites out of cells, cooperating to exert a cytoprotective function. Phase I‐metabolizing enzymes oxidize, reduce, or hydrolyze xenobiotics and drugs, such as aldo‐keto reductases (AKR) and cytochrome P450s (CYPs) encoded by genes regulated by Nrf2. [Table: Downstream targets regulated by Nrf2] Phase II drug‐metabolizing enzymes regulated by Nrf2 are mostly engaged in metabolic pathways through metabolizing xenobiotics via glucuronidation, glutathione conjugation, and sulfation. The primary function of intracellular redox‐balancing proteins is to maintain the cellular levels of glutathione (GSH) and thioredoxin (Trx), which scavenge reactive oxygen species (ROS) and reactive nitrogen species (RNS) in cells.46 Nrf2/Keap1 signaling governs the expression of the xCT (aka SLC7a11 or system xc–),25 which imports cysteine into the cell, along with glutamate‐cysteine ligase (GCL) that catalyzes the rate‐limiting step in glutathione (GSH) biosynthesis.26 Nrf2 regulates glutathione peroxidase (GPx) to maintain peroxides level in order to produce oxidized glutathione (GSSG),27 and glutathione reductase‐1 (GSR1), which reduces GSSG to maintain intracellular levels of reduced GSH.22 The induction of thioredoxin‐1 (Txn1),29 thioredoxin reductases‐1 (TrxR1),30 peroxiredoxins (Prxs),28 and sulfiredoxin‐1 (Srxn1)31 is also subject to Nrf2 regulation for the reduction of oxidized protein thiols and the removal of peroxides. Importantly, NADPH is required as a coenzyme for many xenobiotic metabolism and antioxidant enzymes, including AKR, NAD(P)H: quinone oxidoreductase‐1 (NQO1), and GSR1. Additionally, Nrf2 regulates four NADPH‐generating enzymes, namely glucose‐6‐phosphate dehydrogenase (G6PD), 6‐phosphogluconate dehydrogenase (PGD), isocitrate dehydrogenase‐1 (IDH1), and malic enzyme‐1 (ME1). Heme and quinone both transfer electrons and are therefore direct sources of free radicals and ROS. Moreover, Nrf2 regulates heme oxygenase‐1 (HO‐1) and NQO1 to catalyze heme and quinone degradation.11 Phase III drug transporters extrude endogenous xenobiotics and conjugated metabolites out of cells, including multidrug resistance‐associated proteins (MRPs), P‐glycoprotein (P‐pg), and organic anion‐transporting polypeptide (OATP).37 General function of Nrf2 pathway Nrf2 downstream genes, illustrated in Figure 1, are involved in intracellular redox balancing, xenobiotic response, metabolism, and cell survival. Living cells require cellular homeostasis for metabolic process and the ability to rapidly respond to various stresses imposed by toxic exposure. ROS and toxic metabolites generated by ROS‐mediated cell damage give rise to oxidative stress that is apparently adverse to cell survival and further contribute to the induction of tumorigenesis.47 The Nrf2‐mediated antioxidant response is one of the major cellular defense mechanisms that protect against oxidative stress. The activation of Nrf2 signaling pathway scavenges ROS and RNS by upregulating the expression of multiple drug‐metabolizing enzymes, such as GCL, AKR, UGT, and MRPs. Likewise, Nrf2‐regulated metabolic pathways including pentose phosphate pathway (PPP) and fatty acid pathway, which are essential contributors to the maintenance of cellular redox and normal cell proliferation. Nrf2 in cancer prevention There are abundant evidences that the activation of Nrf2 is able to suppress carcinogenesis, especially in its early stage. Under the physiological condition, Nrf2 maintains the cellular redox homeostasis and exerts anti‐inflammatory functions and further anticancer activities, hence supports cell survival. Nrf2 maintain cellular

Read the complete text